RNA-based therapeutics have shown tremendous promise in disease intervention at the
genetic level, and some have been approved for clinical use, including the recent COVID-19 …

Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to
become an essential approach in treating a variety of infectious, hemato-oncological …

The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires
an urgent deployment of advanced therapeutic options available. The role of …

Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of
exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies …

The first published description of therapeutic applications of antisense oligonucleotide
(ASO) technology occurred in the late 1970s and was followed by the founding of …

Short interfering RNAs (siRNA) are a powerful class of genetic medicines whose clinical
translation can be hindered by their suboptimal delivery properties in vivo. Here, we provide …

Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of
people around the globe and are a major public health burden. Most contemporary …

mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells.
mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy …

Polymer and lipid nanoparticles have been extensively used as carriers to address the
biological barriers encountered in siRNA and mRNA delivery. We summarize the crucial role …